Inovio misses Q3 revenues; CSL rebrands its flu vaccines business;

> Inovio ($INO) missed a Q3 consensus revenue estimate of $29 million from Zack's, instead bringing in $24.2 million. Earnings report

> CSL announced that its flu vaccines business will operate under the brand Seqirus. Release

> France-based Valneva's U.S. subsidiary, Intercell USA, has entered into a distribution and marketing services agreement with VaxServe, a Sanofi Pasteur company, for Valneva's Japanese encephalitis vaccine. Release

> Researchers at Washington University in St. Louis have identified broadly neutralizing antibodies that protect against infection from a range of alphaviruses, including Chikungunya virus. Release

> Caladrius Biosciences ($CLBS) presented additional data at the Society for Immunotherapy of Cancer Annual Meeting supporting its lead candidate for the treatment of metastatic melanoma. Release

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.